Abstract 961P
Background
Galectin-3 plays critical roles in the adhesion, proliferation, and differentiation of tumor cells. Recent data has suggested that galectin-3 plays a role in the development of hepatocellular carcinoma (HCC), however, its prognostic value has not been validated. The aim of our study was to evaluate the clinical and prognostic value of galectin-3 in HCC patients.
Methods
We prospectively enrolled and collected clinicopathologic data and serum samples from 767 HCC patients between 2001 and 2014 at The University of Texas MD Anderson Cancer Center. The cut-off value for low versus high galectin-3 levels was established using ROC curve analysis. The Kaplan-Meier method was used to estimate overall survival (OS) distributions.
Results
The median OS in this cohort was 14.2 months (95% confidence interval [CI]: 12, 16.1 months). OS was significantly associated with clinicopathologic features, including tumor-node-metastasis (TNM) staging (p<0.001), Child-Pugh Score (CPS) (p<0.001), cirrhosis (p<0.001), metastasis (p<0.001), and alpha-fetoprotein (AFP) level (p<0.001). At the time of analysis, the one-year OS rate was 45% (95% CI: 0.4, 0.51) among patients with high galectin-3 levels, and 59% (95% CI: 0.54, 0.63) among patients with low galectin-3 levels. OS was significantly inferior in patients with high galectin-3 levels compared to patients with lower galectin-3 levels (median OS: 10.12 vs 16.49 months; p=0.0022). Higher galectin-3 levels were significantly associated with a higher risk of death (HR =1.29, 95% CI: 1.1, 1.53). Comparison between low (n = 464 patients) and high (n = 302 patients) galectin-3 levels showed that mean serum galectin-3 levels were significantly higher in HCC patients with HCV (p=0.0001), viral-induced hepatitis (p=0.0002), higher Child-Pugh Score (CPS) (p=0.0009), and higher Cancer of the Liver Italian Program (CLIP) score (p=0.0015).
Conclusions
In conclusion, our study shows that serum galectin-3 level is a valid prognostic biomarker candidate and a potential target for therapy in HCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
956P - Phase II study of adjuvant tislelizumab combined with interferon-α and active surveillance in hepatocellular carcinoma patients with microvascular invasion
Presenter: Yixiu Wang
Session: Poster session 18
957P - Interim report of Notable-HCC: A phase Ib study of neoadjuvant PD-1 with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma (HCC)
Presenter: Mingming Li
Session: Poster session 18
959P - Combination therapy of envafolimab and suvemcitug in patients with hepatocellular carcinoma (HCC): Results from a phase II clinical trial
Presenter: Lixia Ma
Session: Poster session 18
960P - Personalized circulating tumor DNA (ctDNA) monitoring for recurrence detection and treatment response assessment in hepatocellular carcinoma (HCC)
Presenter: Maen Abdelrahim
Session: Poster session 18
962P - SBRT improves the efficacy of immuno-checkpoint inhibitors for hepatocellular carcinoma through the activation of IL-6/JAK1-STAT3/PD-L1 axis mediated by MBD3 degradation
Presenter: Weiwei Yan
Session: Poster session 18
963P - Discovery and validation of cfDNA methylation, AFP and ctDNA mutation for the early detection of hepatocellular carcinoma: A multicenter prospective study (ASCEND-Hep)
Presenter: Mingxin Pan
Session: Poster session 18
966P - Potential role of neuropilin-1 in the prognosis, development and risk of invasion in hepatocellular carcinoma patients
Presenter: Tania Payo-Serafín
Session: Poster session 18
967P - The effect of prognosis value of EZH2 (Enhancer Of Zeste Homologue) staining in hepatocellular cancer
Presenter: Mehmet Kidi
Session: Poster session 18